Medical Devices industry M&A deals total $2.38bn in Europe in Q1 2021

Total medical devices industry M&A deals worth $2.38bn were announced in Europe in Q1 2021, led by Thermo Fisher Scientific’s $880.85m asset transaction with Novasep Holding, according to GlobalData’s deals database.

The value marked an increase of 133.3% over the previous quarter and a rise of 362.6% when compared with the last four-quarter average of $514.52m.

Europe held a 7.75% share of the global medical devices industry M&A deal value that totalled $30.7bn in Q1 2021. With a 3.75% share and deals worth $1.15bn, Belgium was the top country in Europe’s M&A deal value across medical devices industry.

In terms of deal activity, Europe recorded 36 deals during Q1 2021, marking a decrease of 5.26% over the previous quarter and a rise of 10.77% over the last four-quarter average. Germany recorded ten deals during the quarter.

Europe medical devices industry M&A deals in Q1 2021: Top deals

The top five medical devices industry M&A deals accounted for 90.5% of the overall value during Q1 2021.

The combined value of the top five M&A deals stood at $2.15bn, against the overall value of $2.38bn recorded for the quarter.

The top five medical devices industry deals of Q1 2021 tracked by GlobalData were:

1) Thermo Fisher Scientific’s $880.85m asset transaction with Novasep Holding

2) The $591m acquisition of Oxford Immunotec by PerkinElmer

3) Savaria’s $409.7m acquisition of Handicare Group

4) The $159m acquisition of Diagenode by Hologic

5) Sino Biopharmaceutical’s acquisition of 60% stake in Softhale for $110m.